Implementing Disease Modifying Therapies in Neurodegenerative Diseases: Lessons From a Survey of Multiple Sclerosis Specialist Services Across England

Abstract excerpt

<title>Abstract</title> <p> <bold>Background</bold> Since 2010, NHS multiple sclerosis (MS) services have transformed to deliver disease modifying therapies (DMTs). To inform future service developments, including intended policy shifts towards care closer to home, we surveyed staff working with different service models across England about their experiences of care delivery. <bold>Methods</bold> We co-design...

Topics

Open a Topic to create a Post that cites this publication.

• Environment
• Genetic Predisposition to Disease
• Methylprednisolone
• Multiple Sclerosis
• Multiple Sclerosis, Relapsing-Remitting
• Neuroprotective Agents
• Quality of Life
• Severity of Illness Index

Identifiers and source

Literature Corpus work

94a6bbb5-8f72-5a0e-8726-026e85b99a2a

DOI

10.21203/rs.3.rs-7924929/v1